All patients had cirrhosis and 107 (75%) were treated with sofosbuvir in combination with an additional NS5A inhibitor such as daclatasvir, ledipasvir or velpatasvir, while the remaining 37 (25%) patients were treated either with SOF + RBV or SOF + RBV + INF. This evidence concerns the gene CBLIF and Cirrhosis.